Eternity in Medical Information -- Medisurf
Items 1 ~ 8 of 1, Page 1 of 1
FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam)
02.05.2019 MERCK
   
1